Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 15.44% | Reduce −6.4% | 5,511,721 | $30.99 | $171M | −377,770 | +$22M |
| FOLD - Amicus | 13.30% | Reduce −1.4% | 10,373,715 | $14.19 | $147M | −150,307 | +$19M |
| BMRN - Biomarin Pharmaceutical | 13.08% | Reduce −18.0% | 1,500,749 | $96.42 | $145M | −330,286 | −$17M |
| BIIB - Biogen | 8.90% | Reduce −0.2% | 380,417 | $258.77 | $98M | −865 | +$447K |
| UTHR - United Therapeutics | 7.86% | Reduce −31.3% | 395,784 | $219.89 | $87M | −180,123 | −$43M |
| ACAD - Acadia Pharmaceuticals | 6.82% | Add +0.2% | 2,409,556 | $31.31 | $75M | +3,763 | +$25M |
| PRTA - Prothena | 5.45% | Add +0.2% | 1,660,057 | $36.34 | $60M | +2,599 | −$20M |
| Revance Therapeutics | 4.16% | Add +0.2% | 5,237,284 | $8.79 | $46M | +8,675 | −$14M |
| Staar Surgical | 3.88% | Add +0.2% | 1,376,950 | $31.21 | $43M | +2,128 | −$12M |
| ALNY - Alnylam Pharmaceuticals | 2.67% | New | 154,437 | $191.41 | $30M | +154,437 | +$30M |
| EHTH - Ehealth | 2.16% | Hold | 2,739,379 | $8.72 | $24M | — | — |
| Sage Therapeutics | 1.94% | Reduce −1.4% | 991,525 | $21.67 | $21M | −14,251 | +$787K |
| Sarepta Therapeutics | 1.75% | Add +113.7% | 200,905 | $96.43 | $19M | +106,875 | +$8M |
| IOVA - Iovance Biotherapeutics | 1.55% | New | 2,106,792 | $8.13 | $17M | +2,106,792 | +$17M |
| ALKS - Alkermes | 1.51% | Hold | 603,400 | $27.74 | $17M | — | — |
| Nevro | 1.46% | Add +94.0% | 750,371 | $21.52 | $16M | +363,539 | +$9M |
| ALGN - Align Technology | 1.38% | Hold | 55,705 | $274.00 | $15M | — | — |
| ANAB - Anaptysbio | 1.33% | Add +59.3% | 686,882 | $21.42 | $15M | +255,658 | +$7M |
| SNDX - Syndax Pharmaceuticals | 0.92% | Hold | 472,600 | $21.61 | $10M | — | — |
| CYTK - Cytokinetics | 0.84% | Hold | 111,717 | $83.49 | $9M | — | — |
| NVCR - Novocure | 0.76% | Reduce −14.9% | 561,908 | $14.93 | $8M | −98,367 | −$2M |
| Verve Therapeutics | 0.73% | New | 575,817 | $13.94 | $8M | +575,817 | +$8M |
| Bluebird Bio | 0.42% | New | 3,333,333 | $1.38 | $5M | +3,333,333 | +$5M |
| Karyopharm Therapeutics | 0.40% | Reduce −10.1% | 5,102,193 | $0.8650 | $4M | −573,683 | −$3M |
| Gossamer Bio | 0.29% | Reduce −46.9% | 3,465,152 | $0.9125 | $3M | −3,065,136 | −$2M |
| RLMD - Relmada Therapeutics | 0.27% | Hold | 732,400 | $4.14 | $3M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.17% | Hold | 64,700 | $29.52 | $2M | — | — |
| VNDA - Vanda Pharmaceuticals | 0.11% | Hold | 278,985 | $4.22 | $1M | — | — |
| Vyne Therapeutics Pipe | 0.09% | New | 445,434 | $2.33 | $1M | +445,434 | +$1M |
| TVTX - Travere Therapeutics | 0.09% | Reduce −33.3% | 110,719 | $8.99 | $995K | −55,350 | −$489K |
| TSHA - Taysha Gene Therapies | 0.08% | New | 529,861 | $1.77 | $938K | +529,861 | +$938K |
| Sight Sciences | 0.08% | New | 173,790 | $5.16 | $897K | +173,790 | +$897K |
| ALDX - Aldeyra Therapeutics | 0.07% | Add +40.2% | 225,465 | $3.51 | $791K | +64,665 | −$283K |
| URGN - Urogen Pharma | 0.03% | Hold | 24,500 | $15.00 | $368K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Kezar Life Sciences | 0.07% | Exit | 0 | $1.19 | $781K | −656,200 | −$781K |
| Holding | 0.04% | Exit | 0 | $14.06 | $381K | −27,100 | −$381K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2